U.S. stocks advanced as traders weighed the implications of Washington’s move in Venezuela, with energy, defense and select tech names in focus. The bid for risk came despite mixed macro signals, underscoring how geopolitical shifts are increasingly steering sector rotations to start the year.
Source: Seeking Alpha
Gold and silver jump on safe‑haven demand amid geopolitical risk
Precious metals led defensive trades as uncertainty around Venezuela added to broader geopolitical risks. The move highlights investors’ preference for hard‑asset hedges when policy and supply dynamics are in flux.
Source: Seeking Alpha
U.S. to meet oil executives on Venezuela; companies cautious on engagement
Washington plans talks with oil majors this week to discuss Venezuela, but companies remain wary given sanctions, legal complexities, and long lead times to restore output. Any material supply response is likely to take years, not months, tempering near‑term market impact.
Source: Seeking Alpha
Vistra to acquire 10 natural gas plants from Cogentrix in $4B deal
Power producer Vistra agreed to buy Cogentrix Energy and a portfolio of 10 gas‑fired plants for $4 billion, deepening its dispatchable generation footprint. The deal underscores ongoing consolidation and the strategic value of flexible capacity as renewables penetration rises.
Source: Seeking Alpha
Nvidia unveils ‘Alpamayo,’ a new autonomous driving AI model at CES
Nvidia introduced Alpamayo, billed as a “thinking” model for autonomous driving, aiming to advance perception and decision‑making for next‑gen vehicles. The debut reinforces Nvidia’s expanding automotive AI stack and keeps investor attention on its broadening end‑market optionality.
Source: Seeking Alpha
Atlanta Fed trims Q4 GDP estimate after weak ISM print
The Atlanta Fed’s GDPNow forecast for Q4 growth was revised lower following a softer ISM Manufacturing reading, adding to evidence of cooling momentum. The downgrade may factor into rate‑cut expectations if broader data confirm a slower pace into early 2026.
Source: Seeking Alpha
Novo Nordisk launches Wegovy pill in U.S. at $149 per month
Novo rolled out an oral version of its blockbuster obesity therapy Wegovy in the U.S. at $149 per month, potentially expanding access versus injections. The price point raises competitive questions for rivals while broadening GLP‑1 category reach into primary care.
Source: Seeking Alpha
You May Also Be Interested In...
Forex.com owner StoneX secures EU MiCA crypto license
Jefferies upgrades IBM to Buy on 2026 software growth outlook
Tesla’s China shipments decline for a second straight year
Exante’s UK unit halts onboarding and new deposits
ESMA kicks off selection for EU OTC derivatives consolidated tape